MRD နှင့် CAR T-Cell ကုထုံးကြား ဆက်ဆံရေးကို နားလည်ခြင်း။
What is MRD in cancer treatment? Measurable Residual Disease, or MRD, is the name for the very few cancer cells that stay in the body after or during treatment. Flow cytometry, polymerase chain reaction (PCR), or next-generati..
အာရုံကြောဆိုင်ရာရောဂါများတွင် Mesenchymal ပင်မဆဲလ်ကုထုံး
Neurological diseases are big problems around the world because they cause a lot of death and disability. Traditional treatments haven't always worked, which has led to a change toward new methods like cell-based therapies. Beca..
အူမကြီးကင်ဆာကို ကုသရန်အတွက် FDA မှ ကလေးထိန်းဆေးဟု သတ်မှတ်ခြင်းကို CART T-Cell Therapy A2B530
In March 2024, a news release said that A2B530 (A2 Biotherapeutics), a CAR T-cell therapy, had been given Orphan Drug Designation to treat colorectal cancer that expresses carcinoembryonic antigen (CEA) and has lost HLA-A*02 expr..
Iovance ၏ Amtagvi အား USFDA မှ အစိုင်အခဲအကျိတ်အတွက် ပထမဆုံး T-cell ကုထုံးအဖြစ် အတည်ပြုထားသည်။
Iovance Biotherapeutics' first-of-its-kind immunotherapy was approved by the FDA. This means that T-cell therapy, which has changed the way some types of blood cancer are treated, can now be used directly on solid tumors.The drug..
Amivantamab-vmjw ကို USFDA မှ EGFR exon 20 တွင် ထည့်သွင်းခြင်း-mutated မဟုတ်သော ဆဲလ်အသေးစား အဆုတ်ကင်ဆာ ညွှန်ပြချက်များအတွက် အတည်ပြုထားသည်
The Food and Drug Administration approved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) in combination with carboplatin and pemetrexed on March 1, 2024. Patients with epidermal growth factor receptor (EGFR) exon 20 insertio..
ဓာတုကုထုံးဖြင့် Osimertinib ကို USFDA မှ EGFR-mutated မဟုတ်သောသေးငယ်သောဆဲလ်အဆုတ်ကင်ဆာအတွက်အတည်ပြုထားသည်
The Food and Drug Administration approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals LP) in combination with platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (la/mNSC..
Lifileucel ကို USFDA မှ ဖယ်ရှား၍မရသော သို့မဟုတ် ပျံ့နှံ့နေသော melanoma အတွက် အတည်ပြုထားသည်။
The Food and Drug Administration granted accelerated approval to lifileucel (Amtagvi, Iovance Biotherapeutics, Inc.) on February 16, 2024. This approval is for adult patients with unresectable or metastatic melanoma who have been..
Tepotinib ကို USFDA မှ metastatic မဟုတ်သောသေးငယ်သောဆဲလ်အဆုတ်ကင်ဆာအတွက်အတည်ပြုသည်။
The Food and Drug Administration officially approved tepotinib (Tepmetko, EMD Serono, Inc.) on February 15, 2024, for adult patients with metastatic non-small cell lung cancer (NSCLC) that had mesenchymal-epithelial transition (M..
Irinotecan liposome ကို USFDA မှ metastatic pancreatic adenocarcinoma ၏ပထမလိုင်းကုသမှုအတွက်အတည်ပြုသည်
The Food and Drug Administration approved irinotecan liposome (Onivyde, Ipsen Biopharmaceuticals, Inc.) with oxaliplatin, fluorouracil, and leucovorin on February 13, 2024, for treating metastatic pancreatic adenocarcinoma as the..
Erdafitinib ကို USFDA မှ ဒေသတွင်းအဆင့်မြင့်သော သို့မဟုတ် metastatic urothelial carcinoma အတွက် အတည်ပြုထားသည်။
Erdafitinib (Balversa, Janssen Biotech) was approved by the Food and Drug Administration on January 19, 2024, for adult patients with FGFR3 genetic changes who have locally advanced or metastatic urothelial carcinoma (mUC). Patie..